Ovarian cancer has been one of the most malignant cancers in women, with the incidence increasing year by year. The most universally used preclinical models, cancer cell lines, and mouse models have many drawbacks making them fundamentally limited in representing the real characteristics of cancer. Numerous anticancer drugs developed from screening cancer cell lines and mouse models have failed in clinical trials. Organoids have been the focus of significant research in recent years, they can replicate the biological features of the parental tumor, and predict individual patient’s response to anticancer drugs. Organoids provide a new in vitro model for basic research and clinical treatment of cancer. In this review, we will focus on the latest progress in the establishment of ovarian cancer organoids and their application for anticancer drug screening.

1.Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer[J]. CA Cancer J Clin, 2011, 61(3): 183-203. DOI: 10.3322/caac.20113.

2.Timmermans M, Sonke GS, van de Vijver KK, et al. No improvement in long-term survival for epithelial ovarian cancer patients: a population-based study between 1989 and 2014 in the Netherlands[J]. Eur J Cancer, 2018, 88: 31-37. DOI: 10.1016/j.ejca.2017.10.030.

3.Domcke S, Sinha R, Levine DA, et al. Evaluating cell lines as tumour models by comparison of genomic profiles[J]. Nat Commun, 2013, 4: 2126. DOI: 10.1038/ncomms3126.

4.Bleijs M, van de Wetering M, Clevers H, et al. Xenograft and organoid model systems in cancer research[J]. EMBO J, 2019, 38(15): e101654. DOI: 10.15252/embj.2019101654.

5.Lee SH, Hu W, Matulay JT, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer[J]. Cell, 2018, 173(2): 515-528. DOI: 10.1016/j.cell. 2018.03.017.

6.Yan HH, Siu HC, Law S, et al. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening[J]. Cell Stem Cell, 2018, 23(6): 882-897. DOI: 10.1016/j.stem. 2018.09.016.

7.Gao D, Vela I, Sboner A, et al. Organoid cultures derived from patients with advanced prostate cancer[J]. Cell, 2014, 159(1): 176-187. DOI: 10.1016/j.cell.2014.08.016.

8.Boj SF, Hwang CI, Baker LA, et al. Organoid models of human and mouse ductal pancreatic cancer[J]. Cell, 2015, 160(1-2): 324-338. DOI: 10.1016/j.cell.2014.12.021.

9.Broutier L, Mastrogiovanni G, Verstegen MM, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening[J]. Nat Med, 2017, 23(12): 1424-1435. DOI: 10.1038/nm.4438.

10.Sachs N, de Ligt J, Kopper O, et al. A living biobank of breast cancer organoids captures disease heterogeneity[J]. Cell, 2018, 172(1-2): 373-386. DOI: 10.1016/j.cell.2017. 11.010.

11.Boretto M, Maenhoudt N, Luo X, et al. Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening[J]. Nat Cell Biol, 2019, 21(8): 1041-1051. DOI: 10.1038/s41556-019-0360-z.

12.Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium[J]. Gastroenterology, 2011, 141(5): 1762-1772. DOI: 10.1053/j.gastro.2011.07.050.

13.Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche[J]. Nature, 2009, 459(7244): 262-265. DOI: 10.1038/nature07935.

14.Hill SJ, Decker B, Roberts EA, et al. Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids[J]. Cancer Discov, 2018, 8(11): 1404-1421. DOI: 10.1158/2159-8290.CD-18-0474.

15.Kopper O, de Witte CJ, Lõhmussaar K, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity[J]. Nat Med, 2019, 25(5): 838-849. DOI: 10.1038/s41591-019-0422-6.

16.Maenhoudt N, Defraye C, Boretto M, et al. Developing organoids from ovarian cancer as experimental and preclinical models[J]. Stem Cell Rep, 2020, 14(4): 717-729. DOI: 10.1016/j.stemcr.2020.03.004.

17.Hoffmann K, Berger H, Kulbe H, et al. Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment[J]. EMBO J, 2020, 39(6): e104013. DOI: 10.15252/embj.2019104013.

18.Nanki Y, Chiyoda T, Hirasawa A, et al. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing[J]. Sci Rep, 2020, 10(1): 12581. DOI: 10.1038/s41598-020-69488-9.

19.de Witte CJ, Espejo Valle-Inclan J, Hami N, et al. Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responses[J]. Cell Rep, 2020, 31(11): 107762. DOI: 10. 1016/j.celrep.2020.107762.

20.Mcgranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future[J]. Cell, 2017, 168(4): 613-628. DOI: 10.1016/j.cell.2017.01.018.

21.Maru Y, Tanaka N, Itami M, et al. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors[J]. Gynecol Oncol, 2019, 154(1): 189-198. DOI: 10.1016/j.ygyno.2019.05.005.

22.Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment[J]. Am J Transl Res, 2014, 6(2): 114-118. DOI: 10.2147/OTT.S64230.

23.Horvath P，Aulner N，Bickle M，et al. Screening out irrelevant cell-based models of disease[J]. Nat Rev Drug Discov, 2016, 15(11): 751-769. DOI: 10.1038/nrd.2016. 175.

24.Chen H, Gotimer K, de Souza C, et al. Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma[J]. Gynecol Oncol, 2020, 157(3): 783-792. DOI: 10.1016/j.ygyno.2020.03.026.